Diligence memo · auto-generated · as of July 2, 2026

Cell Biosciences Inc

Cell Biosciences Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cell Biosciences Inc operates in Biotechnology, based in CUPERTINO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cell Biosciences Inc has raised $62M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $20M on 2010-10-19.

Most recent recorded round closed around 2011-05-11.

Valuation (modeled)modeled

Provath models Cell Biosciences Inc at approximately $516M (range $26M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.79× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era. Within the normal band (79% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 15.1 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).

Modeled value ranks above 83% of those peers.

Closest niche peers: Redpoint Bio CORP, Cardiaq Valve Technologies Inc, Visterra, Inc., Celltex Therapeutics Corp, Crown Bioscience, Inc.

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.